藥明康德(02359.HK)全資子公司擬認購私募基金份額10億元
格隆匯5月20日丨藥明康德(02359.HK)發佈公吿,公司第二屆董事會第十六次會議審議通過《關於認購私募基金份額暨關聯交易的議案》。同意公司全資子公司上海藥明康德新藥開發有限公司以自有資金認繳蘇州藥明匯英一期產業投資基金合夥企業(有限合夥)的基金份額人民幣10億元,並簽署相關投資協議。
公司獨立董事對此關聯交易事項已進行事前認可並發表獨立意見,認為關聯董事已在審議本議案的董事會上回避表決,表決程序符合有關法律法規及《公司章程》的規定。本次交易有利於公司藉助專業投資機構的資源和優勢,加快公司在醫療健康產業的發展步伐,進一步拓寬生態圈、整合產業鏈,為公司發展提供支持和幫助,提高和鞏固公司行業地位,符合公司發展戰略規劃。本次交易是合作各方經友好協商,本着公平公正原則進行的,不存在向關聯方輸送利益的情形,不存在損害公司及股東利益的情形。同意公司實施本次交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.